Search
Close this search box.

Biotech M&A, innovation, public policy in 2024: BioCentury’s latest podcast

Takeout trends, JPM sentiment, innovation drivers & Washington preview 

By Jeff Cranmer, Executive Editor

January 5, 2024 2:15 AM UTC

A flurry of large acquisitions to close out 2023 is likely to carry into the New Year as pharmas continue to show appetite for late-stage assets. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the latest trends in biotech M&A, potential takeout targets for 2024 and the impact on dealmaking of a more aggressive FTC. They also assess sentiment heading into next week’s J.P. Morgan Healthcare Conference, analyze future drivers of innovation in biotech, and preview the year ahead in regulation and public policy.